MapLight Therapeutics, Inc. (MPLT)
Every FINRA and SEC series the site collects for MapLight Therapeutics, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.2M
Short interest
settlement 2026-08-14
5.5
Days to cover
-9.7% vs prior
37.8%
Short share of volume
2026-09-11
699
Fails to deliver
settlement 2026-08-14
-$1.5M
Insider flow, 90 days
1 buys, 8 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 20 settlements in the JSONAs of 14 August 2026, short interest in MPLT is 3,235,957 shares, down 350,239 shares over the last month. Over the last 20 readings it ranged from 198,860 shares (31 October 2025) to 3,586,196 shares (15 July 2026). At the reported average volume of 590K shares a day that is 5.5 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/mplt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 3,235,957 | -9.7% | 589,830 | 5.49 |
| 2026-07-31 | 3,581,497 | -0.1% | 2,170,507 | 1.65 |
| 2026-07-15 | 3,586,196 | +39.1% | 533,984 | 6.72 |
| 2026-06-30 | 2,577,722 | +35.7% | 637,655 | 4.04 |
| 2026-06-15 | 1,899,353 | +21.6% | 291,955 | 6.51 |
| 2026-05-29 | 1,562,112 | +14.8% | 291,390 | 5.36 |
| 2026-05-15 | 1,360,513 | -22.0% | 243,280 | 5.59 |
| 2026-04-30 | 1,744,480 | +3.7% | 356,673 | 4.89 |
| 2026-04-15 | 1,682,848 | +18.6% | 295,926 | 5.69 |
| 2026-03-31 | 1,418,306 | +4.5% | 294,939 | 4.81 |
| 2026-03-13 | 1,357,846 | +0.2% | 143,207 | 9.48 |
| 2026-02-27 | 1,355,099 | -1.4% | 108,974 | 12.44 |
| 2026-02-13 | 1,374,062 | +8.1% | 184,888 | 7.43 |
| 2026-01-30 | 1,271,010 | +17.1% | 215,044 | 5.91 |
| 2026-01-15 | 1,085,107 | -43.8% | 177,940 | 6.10 |
| 2025-12-31 | 1,930,951 | +101.3% | 470,363 | 4.11 |
| 2025-12-15 | 959,036 | +25.6% | 328,019 | 2.92 |
| 2025-11-28 | 763,833 | +87.6% | 201,274 | 3.79 |
| 2025-11-14 | 407,207 | +104.8% | 231,499 | 1.76 |
| 2025-10-31 | 198,860 | +100.0% | 417,361 | 1.00 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of MPLT volume is 37.8%, up 19.6 points over the last five sessions. Over the last 52 readings it ranged from 18.2% (3 September 2026) to 86.3% (7 July 2026). The latest reading is 13.9 points below the 30-session average of 51.6%, on 106K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 40K | 106K | 37.8% | 0 |
| 2026-09-10 | 133K | 187K | 70.8% | 0 |
| 2026-09-09 | 67K | 172K | 39.1% | 618 |
| 2026-09-08 | 50K | 271K | 18.6% | 0 |
| 2026-09-04 | 66K | 221K | 30.1% | 0 |
| 2026-09-03 | 85K | 465K | 18.2% | 1,506 |
| 2026-09-02 | 115K | 474K | 24.2% | 0 |
| 2026-09-01 | 126K | 194K | 65.1% | 462 |
| 2026-08-31 | 79K | 137K | 57.9% | 0 |
| 2026-08-28 | 92K | 144K | 64.3% | 500 |
| 2026-08-27 | 231K | 336K | 68.9% | 0 |
| 2026-08-26 | 122K | 352K | 34.7% | 0 |
| 2026-08-25 | 118K | 301K | 39.3% | 0 |
| 2026-08-24 | 111K | 250K | 44.4% | 2 |
| 2026-08-21 | 71K | 211K | 33.4% | 1,011 |
| 2026-08-20 | 106K | 259K | 40.8% | 0 |
| 2026-08-19 | 123K | 396K | 31.1% | 0 |
| 2026-08-18 | 141K | 203K | 69.6% | 0 |
| 2026-08-17 | 156K | 294K | 53.0% | 0 |
| 2026-08-14 | 146K | 196K | 74.6% | 0 |
| 2026-08-13 | 123K | 157K | 78.4% | 0 |
| 2026-08-12 | 128K | 168K | 76.1% | 0 |
| 2026-08-11 | 86K | 125K | 68.9% | 1,726 |
| 2026-08-10 | 134K | 172K | 77.8% | 10,800 |
| 2026-08-07 | 123K | 178K | 69.0% | 0 |
| 2026-08-06 | 117K | 200K | 58.6% | 3,211 |
| 2026-08-05 | 259K | 378K | 68.3% | 1,116 |
| 2026-08-04 | 142K | 377K | 37.7% | 0 |
| 2026-08-03 | 225K | 484K | 46.4% | 12,547 |
| 2026-07-31 | 298K | 573K | 52.1% | 13,306 |
Fails to deliver
SEC, by settlement date. JSONAs of 14 August 2026, the fails-to-deliver balance in MPLT is 699 shares, up 654 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (12 March 2026) to 92,203 shares (16 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 699 | $11.58 | $8K |
| 2026-08-12 | 45 | $11.98 | $539 |
| 2026-08-04 | 39,705 | $12.55 | $498K |
| 2026-08-03 | 76,189 | $13.02 | $992K |
| 2026-07-31 | 1,300 | $14.03 | $18K |
| 2026-07-30 | 10,000 | $15.02 | $150K |
| 2026-07-27 | 213 | $36.56 | $8K |
| 2026-07-21 | 5,618 | $35.99 | $202K |
| 2026-07-20 | 262 | $37.87 | $10K |
| 2026-07-17 | 7,435 | $37.22 | $277K |
| 2026-07-16 | 92,203 | $37.33 | $3.4M |
| 2026-07-14 | 118 | $36.57 | $4K |
| 2026-07-13 | 94 | $39.32 | $4K |
| 2026-07-10 | 451 | $39.80 | $18K |
| 2026-07-02 | 340 | $36.08 | $12K |
| 2026-07-01 | 23,077 | $35.84 | $827K |
| 2026-06-30 | 10,748 | $34.30 | $369K |
| 2026-06-29 | 15,439 | $33.28 | $514K |
| 2026-06-22 | 13,299 | $28.82 | $383K |
| 2026-06-18 | 2,128 | $29.21 | $62K |
| 2026-06-16 | 533 | $27.96 | $15K |
| 2026-06-15 | 219 | $27.75 | $6K |
| 2026-06-10 | 3 | $29.27 | $88 |
| 2026-06-09 | 7,030 | $29.46 | $207K |
| 2026-06-08 | 15,569 | $28.01 | $436K |
| 2026-06-05 | 8,097 | $30.10 | $244K |
| 2026-06-04 | 728 | $28.34 | $21K |
| 2026-06-03 | 12,727 | $27.34 | $348K |
| 2026-06-01 | 74,917 | $29.31 | $2.2M |
| 2026-04-29 | 4,319 | $30.31 | $131K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONOver the last 90 days MPLT insiders reported 1 open-market buy ($149K) against 8 sells ($1.6M), so the dollar flow leans toward selling. Latest filing: Lillie James Woodruff (Chief Scientific Officer) on 2026-08-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Lillie James Woodruff | Chief Scientific Officer | Grant | 8K | $0.00 | $0 | 210K |
| 2026-08-17 | Kroeger Christopher A. | Chief Executive Officer | Grant | 23K | $0.00 | $0 | 1.3M |
| 2026-08-17 | Kreitzer Anatol | Chief Discovery Officer | Grant | 6K | $0.00 | $0 | 181K |
| 2026-08-17 | Hanson Kristopher | General Counsel | Grant | 8K | $0.00 | $0 | 154K |
| 2026-08-17 | GILLIS JONATHAN | CAO and Interim CFO | Grant | 2K | $0.00 | $0 | 152K |
| 2026-08-17 | GILLIS JONATHAN | CAO and Interim CFO | Grant | 6K | $0.00 | $0 | 150K |
| 2026-08-17 | Foff Erin Pennock | Chief Medical Officer | Grant | 13K | $0.00 | $0 | 312K |
| 2026-08-03 | Lillie James Woodruff | Chief Scientific Officer | Sell | 22K | $12.54 | $277K | 202K |
| 2026-07-28 | Cox Troy | n/a | Buy | 16K | $9.52 | $149K | 16K |
| 2026-07-17 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 900 | $38.17 | $34K | 144K |
| 2026-07-17 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 17K | $37.61 | $638K | 145K |
| 2026-07-17 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 600 | $36.51 | $22K | 162K |
| 2026-07-16 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 1K | $37.44 | $55K | 163K |
| 2026-07-16 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 7K | $36.66 | $256K | 164K |
| 2026-07-15 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 5K | $36.94 | $174K | 171K |
| 2026-07-15 | GILLIS JONATHAN | CAO and Interim CFO | Sell | 5K | $36.13 | $194K | 176K |
| 2026-06-23 | Cox Troy | n/a | Grant | 8K | $0.00 | $0 | 8K |
| 2026-06-23 | Babler Martin | n/a | Grant | 8K | $0.00 | $0 | 8K |
| 2026-05-18 | Kroeger Christopher A. | Chief Executive Officer | Sell | 198 | $28.15 | $6K | 1.4M |
| 2026-05-18 | Kroeger Christopher A. | Chief Executive Officer | Sell | 118K | $27.19 | $3.2M | 1.4M |
| 2026-05-11 | Kroeger Christopher A. | Chief Executive Officer | Sell | 6K | $30.56 | $180K | 1.5M |
| 2026-05-11 | Kroeger Christopher A. | Chief Executive Officer | Sell | 7K | $30.04 | $206K | 1.5M |
| 2026-05-11 | Kroeger Christopher A. | Chief Executive Officer | Sell | 877 | $28.70 | $25K | 1.5M |
| 2026-05-11 | Kroeger Christopher A. | Chief Executive Officer | Sell | 342 | $27.57 | $9K | 1.5M |
| 2026-05-11 | Hanson Kristopher | General Counsel | Sell | 6K | $30.56 | $177K | 162K |
| 2026-05-11 | Hanson Kristopher | General Counsel | Sell | 7K | $30.04 | $210K | 168K |
| 2026-05-11 | Hanson Kristopher | General Counsel | Sell | 846 | $28.70 | $24K | 175K |
| 2026-05-11 | Hanson Kristopher | General Counsel | Sell | 284 | $27.61 | $8K | 176K |
| 2026-05-08 | Kroeger Christopher A. | Chief Executive Officer | Sell | 3K | $29.20 | $94K | 1.5M |
| 2026-05-08 | Kroeger Christopher A. | Chief Executive Officer | Sell | 2K | $28.56 | $45K | 1.5M |
| 2026-05-08 | Kroeger Christopher A. | Chief Executive Officer | Sell | 30K | $27.48 | $814K | 1.5M |
| 2026-05-07 | Lillie James Woodruff | Chief Scientific Officer | Sell | 721 | $28.28 | $20K | 243K |
| 2026-05-07 | Kroeger Christopher A. | Chief Executive Officer | Sell | 5K | $29.15 | $152K | 1.6M |
| 2026-05-07 | Kroeger Christopher A. | Chief Executive Officer | Sell | 15K | $28.47 | $424K | 1.6M |
| 2026-05-07 | Foff Erin Pennock | Chief Medical Officer | Sell | 117 | $29.10 | $3K | 346K |
| 2026-05-07 | Foff Erin Pennock | Chief Medical Officer | Sell | 4K | $28.52 | $123K | 346K |
| 2026-05-06 | Setia Vishwas | Chief Financial Officer | Sell | 2K | $29.07 | $60K | 356K |
| 2026-05-06 | Setia Vishwas | Chief Financial Officer | Sell | 8K | $28.04 | $238K | 358K |
| 2026-05-06 | Lillie James Woodruff | Chief Scientific Officer | Sell | 16K | $29.13 | $478K | 243K |
| 2026-05-06 | Lillie James Woodruff | Chief Scientific Officer | Sell | 8K | $28.04 | $235K | 260K |
| 2026-05-06 | Kroeger Christopher A. | Chief Executive Officer | Sell | 16K | $29.13 | $455K | 1.6M |
| 2026-05-06 | Kroeger Christopher A. | Chief Executive Officer | Sell | 8K | $28.04 | $227K | 1.6M |
| 2026-05-06 | Foff Erin Pennock | Chief Medical Officer | Sell | 16K | $29.13 | $463K | 350K |
| 2026-05-06 | Foff Erin Pennock | Chief Medical Officer | Sell | 8K | $28.04 | $229K | 366K |
| 2026-05-05 | Setia Vishwas | Chief Financial Officer | Sell | 968 | $29.00 | $28K | 367K |
| 2026-05-05 | Setia Vishwas | Chief Financial Officer | Sell | 10K | $28.12 | $279K | 368K |
| 2026-05-05 | Lillie James Woodruff | Chief Scientific Officer | Sell | 963 | $29.00 | $28K | 268K |
| 2026-05-05 | Lillie James Woodruff | Chief Scientific Officer | Sell | 10K | $28.12 | $285K | 269K |
| 2026-05-05 | Kroeger Christopher A. | Chief Executive Officer | Sell | 928 | $29.00 | $27K | 1.6M |
| 2026-05-05 | Kroeger Christopher A. | Chief Executive Officer | Sell | 10K | $28.12 | $268K | 1.6M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON12 Form 144 notices on file for MPLT worth $39.3M at the prices reported; 12 in the last 90 days worth $39.3M. Latest: Lillie James Woodruff filed on 2026-08-03 to sell 22,082 shares ($288K) from 2026-08-03.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-03 | Lillie James WoodruffOfficer | 22K | $288K | 0.053% | 2026-08-03 | Jefferies LLC |
| 2026-07-30 | Novo Holdings A/SFormer Affiliate | 1.6M | $24.0M | 3.528% | 2026-07-30 | Morgan Stanley & Co. LLC |
| 2026-07-17 | ANATOL KREITZEROfficer | 17K | $639K | 0.040% | 2026-07-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-17 | JONATHAN GILLISOfficer | 18K | $687K | 0.043% | 2026-07-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | Anatol KreitzerOfficer | 36K | $1.4M | 0.085% | 2026-07-15 | Morgan Stanley Smith Barney LLC |
| 2026-07-15 | ROBERT MALENKADirector | 18K | $665K | 0.041% | 2026-07-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | Lillie James WoodruffOfficer | 19K | $714K | 0.044% | 2026-07-15 | Jefferies LLC |
| 2026-07-15 | Kroeger Christopher A.Officer | 152K | $5.8M | 0.357% | 2026-07-15 | Jefferies LLC |
| 2026-07-15 | Anatol KreitzerOfficer | 34K | $1.3M | 0.079% | 2026-07-15 | Morgan Stanley Smith Barney LLC |
| 2026-07-15 | Hanson KristopherOfficer | 17K | $626K | 0.039% | 2026-07-15 | Jefferies LLC |
| 2026-07-15 | Jonathan GillisOfficer | 37K | $1.4M | 0.087% | 2026-07-15 | Morgan Stanley Smith Barney LLC |
| 2026-07-15 | Foff Erin PennockOfficer | 48K | $1.8M | 0.113% | 2026-07-15 | Jefferies LLC |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON5 holders above 5% have filed on MPLT, 5 on Schedule 13D (active intent). The largest reported stake is Mark Vorsatz at 49.9% of the class (27,536,011 shares), filed 2026-08-18 for an event on 2026-08-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-18 | 13D/Ano. 2 | Mark Vorsatzindividual | 27.5M | 49.9% | 2026-08-14 |
| 2026-08-18 | 13D/Ano. 2 | Catalyst4, Inc.corporation | 27.5M | 49.9% | 2026-08-14 |
| 2026-08-18 | 13D/Ano. 2 | Robert Brownindividual | 27.5M | 49.9% | 2026-08-14 |
| 2026-08-18 | 13D/Ano. 2 | Ekemini Rileyindividual | 27.5M | 49.9% | 2026-08-14 |
| 2026-08-03 | 13D/Ano. 1 | Mark Vorsatzindividual | 20.9M | 47.9% | 2026-07-30 |
| 2026-08-03 | 13D/Ano. 1 | Catalyst4, Inc.corporation | 20.9M | 47.9% | 2026-07-30 |
| 2026-08-03 | 13D/Ano. 1 | Robert Brownindividual | 20.9M | 47.9% | 2026-07-30 |
| 2026-08-03 | 13D/Ano. 1 | Ekemini Rileyindividual | 20.9M | 47.9% | 2026-07-30 |
| 2026-07-31 | 13D/Ano. 1 | Novo Holdings A/Scorporation | 2.1M | 4.9% | 2026-07-30 |
13F holders
Tracked managers holding MPLT at their latest 13F. JSON4 of the 30 tracked managers held MPLT at their latest 13F, $6.7M in total at quarter-end prices. Millennium Management is the largest at $4.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 129K | $4.6M | 0.00% | new or n/a |
| Citadel Advisors | 2026-06-30 | 43K | $1.5M | 0.00% | -147K |
| Two Sigma Investments | 2026-06-30 | 9K | $322K | 0.00% | -5K |
| Renaissance Technologies | 2026-06-30 | 7K | $249K | 0.00% | new or n/a |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
MapLight Therapeutics, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows MapLight Therapeutics, Inc. (MPLT), SEC CIK 1770069, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-08-03.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-18.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1770069Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 12 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- BBIOBridgeBio Pharma, Inc.
- ROIVRoivant Sciences Ltd.
- CYTKCYTOKINETICS INC
- LGNDLIGAND PHARMACEUTICALS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- SIONSionna Therapeutics, Inc.
- LQDALiquidia Corp
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- HOWLWerewolf Therapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- JNJJOHNSON & JOHNSON
Datasets
Frequently Asked Questions
How much of MPLT is sold short?
What is MPLT's daily short volume?
Does MPLT have fails to deliver?
Are MPLT insiders buying or selling?
Have MPLT insiders filed to sell?
Who owns more than 5% of MPLT?
Which funds hold MPLT?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.